» Articles » PMID: 25511798

Deficiency of Very Large G-protein-coupled Receptor-1 is a Risk Factor of Tumor-related Epilepsy: a Whole Transcriptome Sequencing Analysis

Overview
Journal J Neurooncol
Publisher Springer
Date 2014 Dec 17
PMID 25511798
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

The majority of patients with low-grade glioma (LGG) experience epileptic seizures as their initial symptom, while the underlying mechanisms of tumor-related seizures are still far from being fully understood. In addition to tumor type and location, genetic changes of LGGs are considered to be influential factors in causing epileptic seizures. Nevertheless, the molecular biomarkers associated with tumor-related epilepsy have rarely been identified. RNA sequence data from 80 patients with histologically confirmed LGG were collected from the Chinese glioma genome atlas database and significant differences in expression levels of 33 genes were found. One of the genes, Very large G-protein-coupled receptor-1 (VLGR1), had been previously associated with seizures. Therefore, we investigated the association between LGG-related epilepsy and VLGR1, which played a role in idiopathic epilepsy. The level of VLGR1 expression was compared between patients with epileptic seizures and those without using the reads per kilobase transcriptome per million method. To evaluate the prognostic role of VLGR1 gene expression, the progression-free survival was determined by the Kaplan-Meier method and a multivariate Cox model. We demonstrated that VLGR1 had a significantly lower expression level in patients with epileptic seizures compared to seizure-free patients (p = 0.003). Furthermore, VLGR1 was highly associated with the presence of seizures in a multivariate statistical model. However, VLGR1 could not serve as an independent prognostic factor to determine progression-free survival of LGG patients. Based on RNA sequence data analysis, our results suggest that low expression of VLGR1 is a significant risk factor of epileptic seizures in patients with LGG.

Citing Articles

Single-cell multiomics of neuronal activation reveals context-dependent genetic control of brain disorders.

Liang L, Zhang S, Wang Z, Zhang H, Li C, Duhe A bioRxiv. 2025; .

PMID: 40027724 PMC: 11870544. DOI: 10.1101/2025.02.17.638682.


Multi-omics technologies and molecular biomarkers in brain tumor-related epilepsy.

Du Y, Li R, Fu D, Zhang B, Cui A, Shao Y CNS Neurosci Ther. 2024; 30(4):e14717.

PMID: 38641945 PMC: 11031674. DOI: 10.1111/cns.14717.


Affinity Proteomics Identifies Interaction Partners and Defines Novel Insights into the Function of the Adhesion GPCR VLGR1/ADGRV1.

Knapp B, Roedig J, Roedig H, Krzysko J, Horn N, Guler B Molecules. 2022; 27(10).

PMID: 35630584 PMC: 9146371. DOI: 10.3390/molecules27103108.


Isolation and culturing of primary mouse astrocytes for the analysis of focal adhesion dynamics.

Guler B, Krzysko J, Wolfrum U STAR Protoc. 2021; 2(4):100954.

PMID: 34917973 PMC: 8669101. DOI: 10.1016/j.xpro.2021.100954.


Genetics, pathogenesis and therapeutic developments for Usher syndrome type 2.

Stemerdink M, Garcia-Bohorquez B, Schellens R, Garcia-Garcia G, van Wijk E, Millan J Hum Genet. 2021; 141(3-4):737-758.

PMID: 34331125 DOI: 10.1007/s00439-021-02324-w.


References
1.
You G, Feng L, Yan W, Zhang W, Wang Y, Li S . BCL2A1 is a potential biomarker for postoperative seizure control in patients with low-grade gliomas. CNS Neurosci Ther. 2013; 19(11):882-8. PMC: 6493500. DOI: 10.1111/cns.12148. View

2.
Chang E, Potts M, Keles G, Lamborn K, Chang S, Barbaro N . Seizure characteristics and control following resection in 332 patients with low-grade gliomas. J Neurosurg. 2008; 108(2):227-35. DOI: 10.3171/JNS/2008/108/2/0227. View

3.
van Breemen M, Wilms E, Vecht C . Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management. Lancet Neurol. 2007; 6(5):421-30. DOI: 10.1016/S1474-4422(07)70103-5. View

4.
You G, Sha Z, Yan W, Zhang W, Wang Y, Li S . Seizure characteristics and outcomes in 508 Chinese adult patients undergoing primary resection of low-grade gliomas: a clinicopathological study. Neuro Oncol. 2011; 14(2):230-41. PMC: 3266386. DOI: 10.1093/neuonc/nor205. View

5.
Kunapuli P, Kasyapa C, Hawthorn L, Cowell J . LGI1, a putative tumor metastasis suppressor gene, controls in vitro invasiveness and expression of matrix metalloproteinases in glioma cells through the ERK1/2 pathway. J Biol Chem. 2004; 279(22):23151-7. DOI: 10.1074/jbc.M314192200. View